[Long acting insulin analogues: results of clinical studies with insulin glargine].
The insulin treatment in type 2 diabetes mellitus (DM 2) is an explosive subject within health economics. This article discusses the significance of treating DM 2 patients with long-acting insulin analogues. Several studies have shown that the therapy with insulin glargine ist associated with a markedly lower rate of hypoglycaemia compared to NPH insulin. As the improvement of HbA1c is accompanied by a higher risk for hypoglycaemia, this goal is accomplished more effectively and safely with long acting insulin analogues.
Fritsche
A
A
Medizinische Klinik am Universitätsklinikum Tübingen, Abteilung IV. Andreas.Fritsche@med.uni-tuebingen.de
D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005858:Germany; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D011379:Prognosis; D012307:Risk Factors
D003692:Delayed-Action Preparations; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; C517652:hemoglobin A1c protein, human